Abstract
Nowadays, diabetes mellitus (DM) is viewed as a condition of progressive loss of beta cell mass or function caused by the interaction of genetic and environmental factors. In all types of DM, hyperglycemia is associated with the development of the same complications, although their progression may vary. Over recent decades, it has been recognized that the gastrointestinal (GI) tract, historically considered an alimentary organ, plays a crucial role in the regulation of glucose metabolism. It contributes to the maintenance of metabolic homeostasis by controlling the rate of glucose being delivered to the circulation and by secreting multiple hormones from the enteroendocrine cells (EEC) and neurons in the GI tract. GI peptides are involved in the control of gut secretion, nutrient absorption, GI motility and growth, and signaling pathways within the gut–brain axis. The function of the GI system is under control of the autonomic nervous system (ANS), composed of three interdependent parts: sympathetic, parasympathetic, and enteric nervous system (ENS). In addition, current understanding of the relationship between gut microbiota, obesity, and type 2 DM has improved our knowledge about metabolic homeostasis. The gut microbiota has emerged as a potential treatment target in obesity and type 2 DM.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. IDF Diabetes Atlas: global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–49.
American Diabetes Association. Standards of medical care in diabetes—2017. Classification and diagnosis of diabetes. Diabetes Care. 2017;40(Suppl 1):S11–24.
Schwartz SS, Epstein S, Corkey BE, Grant SFA, Gavin JR III, Aguilar RB. The time is right for a new classification system for diabetes: rationale and implications of the b-cell–centric classification schema. Diabetes Care. 2016;39:179–86.
Leslie RD, Palmer J, Schloot NC, Lernmark A. Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia. 2016;59:13–20.
American Diabetes Association. Standards of medical care in diabetes—2017. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(Suppl 1):S64–74.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologist and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract. 2017;23(2):207–38.
Phillips RJ, Powley TL. Innervation of the gastrointestinal tract: patterns of aging. Auton Neurosci. 2007;136(1–2):1–19.
Mostafa RM, Moustafa YM, Hamdy H. Interstitial cells of Cajal, the Maestro in health and disease. World J Gastroenterol. 2010;16(26):3239–48.
Al-Shboul OA. The importance of interstitial cells of Cajal in the gastrointestinal tract. J Gastroenterol. 2013;19(1):3–15.
Ward SM, Sanders KM. Involvement of intramuscular interstitial cells of Cajal in neuroeffector transmission in the gastrointestinal tract. J Physiol. 2006;576(3):675–82.
Uranga-Ocio JA, Bastus-Diez S, Delkader-Palacios D, Garcia-Cristobal N, Leal-Garcia MA, Abalo-Delgado RA. Enteric neuropathy associated to diabetes mellitus. Rev Esp Enferm Dig. 2015;107(6):366–73.
Margolis KG, Gershon MD, Bogunović M. Cellular organization of neuroimmune interactions in the gastrointestinal tract. Trends Immunol. 2016;37(7):487–501.
Yarandi S, Srinivasan S. Diabetic gastrointestinal motility disorders and the role of enteric nervous system: current status and future directions. Neurogastroenterol Motil. 2014;26(5):611–24.
Vučković-Rebrina S. Značaj apoptoze i neurotrofina u bolnoj i bezbolnoj dijabetičkoj polineuropatiji u bolesnika s tipom 2 šećerne bolesti [dissertation]. Zagreb: University of Zagreb; 2011. Croatian.
Vučković-Rebrina S, Barada A, Smirčić-Duvnjak L. Diabetic autonomic neuropathy. Diabetol Croat. 2013;42–3:73–9.
Dockray GJ, Varro A. Editorial overview: gastrointestinal: gut hormones—from bench to bedside. Curr Opin Pharmacol. 2016;31:v–vi.
Brubaker PL. Gut hormones fulfill their destiny: from basic physiology to the clinic. Annu Rev Physiol. 2014;76:515–7.
Côté CD, Zadeh-Tahmasebi M, Rasmussen BA, Duca FA, Lam TK. Hormonal signaling in the gut. J Biol Chem. 2014;289(17):11642–9.
Boguszewski CL, van der Lely AJ. The role of the gastrointestinal tract in the control of energy balance. Transl Gastrointest Cancer. 2015;4(1):3–13.
Churm R, Davies JS, Stephens JW, Prior SL. Etiology and pathophysiology/obesity comorbidity ghrelin function in human obesity and type 2 diabetes: a concise review. Obes Rev. 2017;18:140–8.
Colldén G, Tschöp MH, Müller TD. Therapeutic potential of targeting the ghrelin pathway. Int J Mol Sci. 2017;18(4):798.
Moehlecke M, Canani LH, Silva LO, Trindade MRM, Friedman R, Leitão CB. Determinants of body weight regulation in humans. Arch Endocrinol Metab. 2016;60(2):152–62.
Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes Obes Metab. 2016;18:203–16.
Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–37.
Holst JJ, Gribble F, Horowitz M, Rayner CK. Roles of the gut in glucose homeostasis. Diabetes Care. 2016;39:884–92.
Psichas A, Reimann F, Gribble FM. Gut chemosensing mechanisms. J Clin Invest. 2015;125:908–17.
Gribble FM, Reimann F. Enteroendocrine cells: chemosensors in the intestinal epithelium. Annu Rev Physiol. 2016;78:277–99.
Fournel A, Marlin A, Abot A, et al. Glucosensing in the gastrointestinal tract: impact on glucose metabolism. Am J Physiol Gastrointest Liver Physiol. 2016;310:G645–58.
Maggs D, MacDonald I, Nauck MA. Glucose homeostasis and the gastrointestinal tract: insights into the treatment of diabetes. Diabetes Obes Metab. 2008;10:18–33.
Wu T, Rayner CK, Young RL, Horowitz M. Gut motility and enteroendocrine secretion. Curr Opin Pharmacol. 2013;13(6):928–34.
Wu H, Tremaroli V, Backhed F. Linking microbiota to human diseases: a systems biology perspective. Trends Endocrinol Metab. 2015;26:758–70.
Munro N. Gut microbiota: its role in diabetes and obesity. Diab Prim Care. 2016;18:1–6.
Mikkelsen KH, Frost M, Bahl MI, et al. Effect of antibiotics on gut microbiota, gut hormones and glucose metabolism. PLoS One. 2015;10:e0142352.
Allin KH, Nielsen T, Pedersen O. Gut microbiota in patients with type 2 diabetes mellitus. Eur J Endocrinol. 2015;172:R167–77.
Baothman OA, Zamzami MA, Taher I, Abubaker J, Abu-Farha M. The role of gut microbiota in the development of obesity and diabetes. Lipids Health Dis. 2016;15:108.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Duvnjak, L.S., Rebrina, S.V. (2018). Diabetes Mellitus. In: Duvnjak, M., Smirčić-Duvnjak, L. (eds) Gastrointestinal Complications of Diabetes . Clinical Gastroenterology. Humana Press, Cham. https://doi.org/10.1007/978-3-319-75856-5_1
Download citation
DOI: https://doi.org/10.1007/978-3-319-75856-5_1
Published:
Publisher Name: Humana Press, Cham
Print ISBN: 978-3-319-75855-8
Online ISBN: 978-3-319-75856-5
eBook Packages: MedicineMedicine (R0)